Share on

Middle East & Africa Zika Virus Vaccines Market Research Report - Segmented By Type, End-user, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 5820
Pages: 145
Formats: report pdf report excel report power bi report ppt

MEA Zika Virus Vaccines Market Size (2023 to 2028)

The Middle East & Africa Zika Virus Vaccines Market was worth USD 1.45 billion in 2023 and estimated to be growing at a CAGR of 6.24%, to reach USD 1.96 billion by 2028.

Government initiatives, a large population of the patients, an increase in healthcare expenditure, and disposable income are the factors driving the Middle East and Africa (MEA) Zika virus vaccines market. Reimbursement, favorable government policies, close attention towards pregnant women, rise in incidences of the Zika virus, advanced technology developments in health care are also driving the MEA Zika virus vaccine market. An increase in understanding of Zika virus infection and investments made by the private companies drives the regional MEA Zika virus vaccine market.

World Health Organization (WHO announced that the Zika virus would not be a widespread ailment in the coming years, which is the factor restraining the regional vaccines market. The requirement of the massive number of investments in the development of vaccines may also suppress the growth of the MEA Zika Virus Vaccines Market. Lack of awareness is projected to hinder the growth of this business further.

The opportunities the market offers are the need to prevent the virus, immunization of vaccines, and treatment for Zika linked congenital disabilities, i.e., newborn babies who are diagnosed with this virus, and the further spread of Zika virus infection. The factors mentioned in the challenges have resulted in the pharmaceutical organizations' interest to invest and capitalize on the growth challenges. 

The crucial challenges that come in face to face with the healthcare and government in the regions like the Middle East & Africa are spreading the Zika virus. The deficiency of preventive and effective medical solutions towards the treatment may hinder the expansion of this regional market in the coming years. To overcome these challenges, the government and other research institutes are motivating and supporting the pharmaceutical regions to invest, funds, and providing infrastructure and outsourcing of labor. The in-depth analysis provides an insight underlying the growth and challenges.

This research report on the MEA Zika Virus Vaccines Market has been segmented & sub-segmented into the following categories:

By Type:

  • Therapeutic Vaccines
  • Preventive Vaccines

By End-User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, Middle East and Africa have the second-largest share in terms of revenue due to countries like the USA, China, and the UK are investing in the region. This increased financial revenue will aid the healthcare sectors in this region.

Companies playing a key role in the MEA Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline plc., Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample